avastin: Clinical Trials

30 trials of avastin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 3 terminated, 2 unknown, 1 enrolling by invitation. 30 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 430Completed 23, Terminated 3, Unknown 2, Enrolling by invitation 1, Withdrawn 1

Follow avastin: new trials by email Literature Review of avastin trials Research Report on avastin

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Atezolizumab, Bevacizumab - Hepatocellular Carcinoma, Hepatocellular Cancer
Phase 4Enrolling by invitationThe Methodist Hospital Research Institute242023-01-302026-10-08
Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
Intravitreal ranibizumab, Intravitreal bevacizumab - Diabetic Macular Edema, Macular Ischemia
Phase 4TerminatedCairo University52021-11-262023-02-16
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation - Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
Phase 4CompletedCairo University432021-03-302024-01-19
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Bevacizumab - Ovarian Neoplasms, Peritoneal Neoplasms
Phase 4CompletedHoffmann-La Roche1002018-12-052025-06-26
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
Bevacizumab, Ranibizumab, Aflibercept - Diabetic Macular Edema, Cataract
Phase 4CompletedBay Area Retina Associates162018-11-152025-09-12
Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Bevacizumab - Diabetic Macular Edema, Ischemic Maculopathy
Phase 4CompletedCairo University312017-10-232020-01-30
Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO
Dexamethasone intravitreal implant, Bevacizumab Injectable Product - Diabetic Macular Edema, Diabetic Retinopathy
Phase 4CompletedLions Eye Institute, Perth, Western Australia592017-02-072020-11-09
Strategies for Management of Recurrent Pterygium
Bevacizumab, 5 fluorouracil - Recurrent Pterygium
Phase 4UnknownUniversity of Nottingham252017-01-012017-11-14
Intranasal Bevacizumab for HHT-Related Epistaxis
Bevacizumab, Placebo (Saline) - HHT, Hereditary Hemorrhagic Telangiectasia
Phase 4CompletedStanford University402014-08-042021-09-01
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
Ozurdex, Bevacizumab - Diabetic Macular Edema
Phase 4CompletedRaj K. Maturi, MD452014-01-012015-12-01
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
avastin, mFOLFOX6 - Colorectal Neoplasms
Phase 4CompletedXu jianmin2412013-10-012019-12-17
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
gemcitabine, cisplatin and bevacizumab - Non-Small Cell Lung Cancer (NSCLC)
Phase 4CompletedFundacion Clinic per a la Recerca Biomédica192013-07-012016-10-05
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Bevacizumab - Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 4CompletedKing Khaled Eye Specialist Hospital502013-06-012021-12-03
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
5-FU based doublet chemotherapy, bevacizumab - Colorectal Cancer
Phase 4CompletedHoffmann-La Roche502012-10-162017-06-09
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
Bevacizumab, Paclitaxel, Carboplatin - Ovarian Cancer
Phase 4UnknownNational Cancer Institute, Naples4002012-10-012023-03-24
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
intravitreal injection of bevacizumab - Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Phase 4CompletedKhon Kaen University182012-08-012013-04-26
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Bevacizumab - Neoplasms
Phase 4CompletedHoffmann-La Roche952012-07-132020-11-05
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
Bevacizumab, Vitrectomy, Sham injection - Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment
Phase 4CompletedNihon University692012-05-012014-07-14
Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
Bevacizumab, dexamethasone intravitreal implant - Diabetic Macular Edema
Phase 4CompletedMaturi, Raj K., M.D., P.C.402011-03-012014-10-29
Use of Bevacizumab in Trabeculectomy Surgery
Bevacizumab, Control - Glaucoma, Optic Neuropathy
Phase 4CompletedSunnybrook Health Sciences Centre592010-06-012023-08-21

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (5)  ·  Diabetic Retinopathy (4)  ·  Breast Neoplasms (2)  ·  Glaucoma (2)  ·  Macular Edema (2)  ·  Ovarian Neoplasms (2)  ·  Vitreous Hemorrhage (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cataract (1)  ·  Epistaxis (1)  ·  Fallopian Tube Neoplasms (1)  ·  Fibrosis (1)  ·  Liver Neoplasms (1)  ·  Macular Degeneration (1)

Sponsors

Hoffmann-La Roche (6)  ·  Cairo University (3)  ·  Maturi, Raj K., M.D., P.C. (2)  ·  Bay Area Retina Associates (1)  ·  Fundacion Clinic per a la Recerca Biomédica (1)  ·  Genentech, Inc. (1)  ·  Hospices Civils de Lyon (1)  ·  Khon Kaen University (1)  ·  King Khaled Eye Specialist Hospital (1)  ·  Lions Eye Institute, Perth, Western Australia (1)  ·  Medical University of Vienna (1)  ·  National Cancer Institute, Naples (1)  ·  Nihon University (1)  ·  Nova Scotia Health Authority (1)  ·  Oslo University Hospital (1)

Countries

United States (7)  ·  Canada (4)  ·  Egypt (3)  ·  Austria (2)  ·  Brazil (2)  ·  China (2)  ·  France (2)  ·  Italy (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Germany (1)

Top investigators

Raj K Maturi, MD (3)  ·  Ahmed A Abdel-Kader, MD, PhD (2)  ·  Ahmed A Mohalhal, MD, PhD (2)  ·  Ayman G Elnahry, MD, PhD (2)  ·  Ahmed AA Abdel Kader, PhD (1)  ·  Andreas Moan (1)  ·  Angus Turner, FRANZCO (1)  ·  Ayman GA Elnahry, MSc (1)  ·  Ayumu Manabe (1)  ·  Caesar Luo, MD (1)  ·  Catherine Birt, MD, FRCSC (1)  ·  Ciro Gallo, M.D. (1)  ·  Francesco Perrone, M.D., Ph.D. (1)  ·  Gennaro Daniele, M.D., Ph.D. (1)

Results publications

PMID 32411431, PMID 31139483, PMID 32427087, PMID 20416952, PMID 22080911, PMID 22176513, PMID 22250209, PMID 22330964, PMID 24768239, PMID 25892934, PMID 26338819, PMID 26565927, PMID 26605370, PMID 26903223, PMID 28114569, PMID 28168567, PMID 29080915, PMID 31227330, PMID 32584384, PMID 32749938, PMID 33206392, PMID 33784213, PMID 33931498, PMID 34124270, PMID 34189816, PMID 34462317, PMID 34498344, PMID 3523356, PMID 39415516, PMID 42575837, PMID 6182936, PMID 6521986

NIH funding

2009 (1)